🇺🇸 FDA

Intelligence · Clinical Pipeline

Metabolic & obesity · Phase II

Metabolic & obesity programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
210

Quick answer

Metabolic & obesity Phase II programs: NovaPharmaNews indexes 210 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 2 of 5

  1. Cohort A: ORMD-0801

    ORAMED PHARMACEUTICALS INC.

    T2DM (Type 2 Diabetes Mellitus)

    phase 2 small molecule completed

    1 trial

  2. DA-302168S

    Chendu DIAO Pharmaceutical Group CO., LTD.

    Overweight and Obesity

    phase 2 small molecule active

    1 trial

  3. DCCR (diazoxide choline) extended-release tablets

    SOLENO THERAPEUTICS INC

    SH2B1 Deficiency Obesity

    phase 2 small molecule active

    1 trial

  4. DIABECELL(R)

    Otsuka Beijing Research Institute

    Type 1 Diabetes

    phase 2 other completed

    1 trial

  5. DM199

    DiaMedica Therapeutics

    Diabetes Type 2

    phase 2 small molecule completed

    1 trial

  6. Diamyd

    Wuhan Createrna Science and Technology Co., Ltd

    Latent Autoimmune Diabetes in Adults (LADA)

    phase 2 small molecule active

    1 trial

  7. EXENATIDE

    Disc Medicine

    Gestational diabetes

    phase 2 small molecule active

    1 trial

  8. EXENATIDE , VERAPAMIL

    Disc Medicine

    type 1 diabetes mellitus

    phase 2 small molecule active

    1 trial

  9. Eat Well Live Well Nutrition Program

    Grace Therapeutics

    Diabetes or Diabetes Prevention

    phase 2 other completed

    1 trial

  10. Evogliptin

    Samsung Bioepis NL B.V.

    Type2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  11. External Chinese medicine

    Universal Integrated

    Diabetic Foot

    phase 2 small molecule active

    1 trial

  12. Fasiglifam

    Takeda

    Type 2 Diabetes Mellitus

    phase 2 small molecule terminated

    2 trials

  13. G-Pen Mini™ (glucagon injection)

    Xeris Biopharma Holdings

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    2 trials

  14. GIP/GLP-1a

    United Therapeutics Europe Ltd

    Non-Alcoholic Fatty Liver Disease

    phase 2 small molecule active

    1 trial

  15. GK1-399 (formerly TTP399)

    vTv Therapeutics

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  16. GL0034 4 mg/ml, 1 ml per vial, GL0034 3 mg/ml, 1 ml per vial, Same solution as for GL0034 without drug substance; solution for subcutaneous injection; volume identical to dose of test product, GL0034 1mg/ml, 0.6ml per vial, GL0034 1 mg/ml, 1 ml per vial

    Lacuna Pharma Pty Ltd

    Type 2 diabetes mellitus

    phase 2 small molecule active

    1 trial

  17. GSBR-1290

    Structure Therapeutics

    Overweight or Obesity

    phase 2 small molecule completed

    1 trial

  18. GSK2330672

    ELITE PHARMACEUTICALS INC /NV/

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  19. GWP42004

    Jazz Pharmaceuticals Ireland Limited

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  20. GZR102

    Gan & Lee Pharmaceuticals.

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule active

    1 trial

  21. Grafalon 20 mg/ml koncentrát pro infuzní roztok

    The George Institute

    Type 1 diabetes

    phase 2 small molecule active

    1 trial

  22. High Dose SAB-142

    SAB Biotherapeutics

    Type 1 Diabetes

    phase 2 small molecule active

    1 trial

  23. Humalog

    HALOZYME THERAPEUTICS, INC.

    Type 1 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  24. Humalog

    HALOZYME THERAPEUTICS, INC.

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  25. ILT-101 liquide, Placebo of ILT-101, CICLOSPORIN

    Pari Pharma GmbH

    Patient with newly diagnosed (≤ 3 months) type 1 diabetes stage 3

    phase 2 small molecule active

    1 trial

  26. IOHEXOL , Placebo to match LY3437943, Retatrutide

    Eli Lilly Co.

    Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  27. ISIS 113715

    IONIS PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    5 trials

  28. ISIS-APOCIIIRX

    IONIS PHARMACEUTICALS INC

    Type 2 Diabetes

    phase 2 small molecule terminated

    1 trial

  29. ISIS-FGFR4RX

    IONIS PHARMACEUTICALS INC

    Obesity

    phase 2 small molecule completed

    1 trial

  30. ISIS-GCCRRx

    IONIS PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  31. ISIS-GCGRRx

    IONIS PHARMACEUTICALS INC

    Type 2 Diabetes

    phase 2 small molecule completed

    1 trial

  32. ISIS-GCGRRx - Dose Level 1

    IONIS PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  33. ISIS-GCGRRx- Dose Level 1

    IONIS PHARMACEUTICALS INC

    Type 2 Diabetes

    phase 2 small molecule completed

    1 trial

  34. ISIS-PTP1BRx

    IONIS PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  35. IW-1973

    Cyclerion Therapeutics

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  36. IW-1973

    Akebia Europe Limited

    Type 2 Diabetes Mellitus With Diabetic Nephropathy

    phase 2 small molecule completed

    1 trial

  37. IW-9179

    IRONWOOD PHARMACEUTICALS INC

    Diabetic Gastroparesis

    phase 2 small molecule completed

    1 trial

  38. Insulin lispro

    HALOZYME THERAPEUTICS, INC.

    Diabetes Mellitus, Type II

    phase 2 small molecule completed

    1 trial

  39. Insulin lispro

    HALOZYME THERAPEUTICS, INC.

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    2 trials

  40. Intravitreal Aflibercept Injection

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 2 small molecule completed

    1 trial

  41. Investigational new drug company code: BGS649

    Mereo BioPharma Group plc

    Obese Hypogonadotropic Hypogonadism

    phase 2 small molecule terminated

    1 trial

  42. Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy

    Eledon Pharmaceuticals

    Type 1 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  43. JMKX000623

    Jemincare

    Diabetic Peripheral Neuropathic Pain

    phase 2 small molecule active

    1 trial

  44. Jiangtang Tiaozhi recipe

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Type2 Diabetes

    phase 2 small molecule active

    1 trial

  45. KAI-7535

    Kailera Therapeutics

    Obesity

    phase 2 small molecule active

    2 trials

  46. KVD001 Injection

    Kalvista Pharmaceuticals (Ireland) Limited

    Diabetic Macular Edema

    phase 2 small molecule completed

    2 trials

  47. Kerendia 10 mg film coated tablets, Kerendia 20 mg film-coated tablets, Finerenone/Kerendia 10mg and 20mg Placebo equal to test product except active substance, Empagliflozin/Jardiance 10mg Placebo equal to test product except active substance, Jardiance 10 mg film-coated tablets

    Bayer AG

    Chronic kidney disease in type 2 diabetes mellitus

    phase 2 small molecule active

    1 trial

  48. LB54640

    Rhythm Pharmaceuticals Netherlands B.V.

    Hypothalamic Obesity

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many metabolic & obesity Phase II programs exist?

210 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.